| Identification | Back Directory | [Name]
BIBN 99 | [CAS]
145301-48-0 | [Synonyms]
BIBN 99
N-[3-[1-[2-(8-chloro-6-oxo-5~{H}-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide
Pentanamide, N-[3-[1-[2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]-4-piperidinyl]propyl]-N-ethyl-2,2-dimethyl- | [Molecular Formula]
C31H42ClN5O3 | [MDL Number]
MFCD00867672 | [MOL File]
145301-48-0.mol | [Molecular Weight]
568.15 |
| Hazard Information | Back Directory | [Description]
Bibn 99 is a lipophilic and selective muscarinic M2 receptor antagonist with applications to cognitive performance and Alzheimer's Disease. | [Uses]
BIBN-99 is a selective, BBB-penetrable and competitive muscarinic M2 receptor antagonist. BIBN-99 improves cognitive performancein rats with traumatic brain injury[1][2]. | [References]
[1] Doods H, et al. Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur J Pharmacol. 1993 Sep 21;242(1):23-30. DOI:10.1016/0014-2999(93)90005-3
[2] Pike BR, et al. Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats. Brain Res. 1995 Jul 17;686(1):37-43. DOI:10.1016/0006-8993(95)00448-y |
|
|